Get in contact
Please do not apply for job roles using the above form
All recruitment applications must be submitted via our hiring process. For open positions and applications, please visit our Careers page.
Visit us
Geneva
Rue François-Bellot 6, 1206
Nantes
Le Palace, 4 rue Voltaire, 44000
Paris
14/16 Bd Poissonnière, 75009 Paris
London
1 Pancras Sq, London N1C 4AG
Boston
245 Main Street Cambridge MA 02142
New York
831 Broadway, Unit 3R, 10003
Meet us at an event
Meet us at Booth #741 at AACR: SABCS
Come talk to us to explore how AI digital pathology could revolutionalize access to precision medicine for patients.
Press kit
Boilerplate
Owkin is an AI biotechnology company on a mission to find the right treatment for every patient. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools.
We use federated data access to unlock valuable insights from patient data while protecting patient privacy and securing proprietary data. We integrate the best of human and artificial intelligence to answer the research questions challenging biopharma and academic researchers.
Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).
Media contact
Owkin’s experts are available to comment on topics related to medical research and Al.
For international media requests, please contact darius.meadon@owkin.com
For French media requests, please contact malika.labou-ext@owkin.com
About our founder
Thomas leads Owkin as CEO. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and former member of Ari Melnick’s lab at the Weill Cornell Medical College. He ensures that patient health is prioritized when developing breakthrough medical technologies, bringing a patient-centric approach to each Owkin project.
FAQs